The most up-to-date statistics in 2014 showed that heart disease (cardiovascular disease) is the top killer of Americans, and considered a significant threat to the people of the world. 1 In the past decade, the death rate of heart disease has decreased approximately30% to 40% 2 ; however,many of the first, silent myocardial infarctions were not reported. Meanwhile the risk factors of heart disease are increasing.
Kaseer et al. studied the relationship between pneumococcal vaccination and ST segment elevation myocardial infarction (STEMI). 3 STEMI is a type of heart attack, in which the coronary artery is completely blocked by blood clots, resulting ininsufficient blood supply to heart muscle. This type of heart attack, recognized by an electrocardiogram test, shows a characteristic elevation in the ST segment. It has been shown that STEMI can be concomitant with atherosclerosis. 4, 5 The connection between atherosclerosis and infection has been known for decades; however, the relevance between pneumococcal disease and coronary heart disease was first reported in 2000. Musher et al. found that 5 out of 100 patients with pneumococcal pneumonia had acute myocardial symptoms. 6 Dr. Musher and colleagues had a hypothesis that the physical stress caused by pneumonia could trigger cardiovascular events, which was proved in a 5-year study on 170 patients with pneumococcal pneumonia. 7 Among the patients, 33 (19.4%) had more than one major cardiac event, 20 (11.8%) had myocardial infarction (MI), and 13 (7.6%) had newonset or worsening congestive heart failure (CHF) without MI or arrhythmias. This study also reported a higher mortality for patients with both pneumonia and cardiac events than those with pneumonia alone (P<0.008).This research also suggested a problem that physicians usually unintentionally overlook: the coexistence of pulmonary and cardiac disease. The unifying diagnosis leads them to make the decision of one diagnosis rather than the other.
Why is severe lung inflammation associated with coronary inflammation, and even acute MI (AMI)? With coronary heart diseaseor other cardiovascular disease, the human body doesn't have enough physiological reserve to fight flu or pneumonia.There is a high chance that the plaques in the arteries will rupture and form clots that will block blood vessels, which is a consequence of atherosclerosis. Additionally, lung infection restricts the utilization of oxygen, which makes the heart beat harder than normal to pump blood and transfer oxygen throughout body. An efficient way to avoid flu or pneumonia is vaccination.A studydemonstrated this on low density lipoprotein (LDL) receptor nullmice, showing that vaccination against Streotococcuspneumoniaereduced the extent ofatherosclerotic lesions. 8 Pneumococcal vaccination decreased the extent of atherosclerotic lesions, additionally, plasma from these mice had an enhanced capacity to block the binding of oxidized LDL to macrophagesdue to molecular mimicry between S.pneumoniae and oxidized LDL.
Kaseer et al. mentioned the work of Lamontagne and colleagues. As early as 2008, the hospital-based case-control study showed that myocardial infarction rate was decreased more than 50% if one dose of pneumococcal vaccination had been given for 2 years or more prior to the patients' hospital admissions. 9 However, the limitation of this study is obvious, many of the cardiovascular risk factors were not recorded, such as smoking, medication use, obesity, exercise and diet, and so on. Besides, the patients of this study were exclusively mostly of white males, which also limits the external validity of the conclusion. After this study, a number of research projects were conducted to confirm the protective effect of pneumococcal vaccination on heart disease. Some studies showed similar results with the initial report. 10, 11 However, there were also a few conflicting results.
One opposite example was a study on male patients aged 45 years or older in 2010. Researchers found no significant difference betweenincidence of first acute MI when comparing pneumococcal vaccinated and unvaccinated patients. 12 In 2013, Ochoa-Gondar et al. concluded that 23-valent pneumococcal polysaccharide vaccine (PPV23) couldn't protect ≥60 years-old patients from AMI. In another study, as described by Kasser et al., 473 patients that underwent STEMI during a period of 4 years were studied. They found patients with pneumococcal vaccination had an increased risk of mortality(HR=2.08; 95% CI 1.34-3.23; p=0.001), but no significant association of immunization with increased mortality was found. Although in this study, pneumococcal vaccinated patients were relatively older, with CHF history, diabetes, hypertension, hyperlipidemia,and chronic obstructive pulmonary disease as well as prior coronary artery disease and strokes. When compared to the non-vaccinated group, the work of Kasser et al. brought new insight to clinical practice.
Given the diverse limitations in all the individual studies, it is hard to draw a straightforward conclusion onwhether pneumococcal vaccination affects heart disease or not. It is more like a case to case situation. Until August of 2013, the American Heart Association still suggests that flu or pneumonia vaccination is an effective way to defend heart disease, especially for those who are elderly or already have heart disease. 
